RedHill Biopharma Debt-to-Equity Ratio Growth & History (RDHL)

RedHill Biopharma's debt-to-equity ratio was 0.25 for fiscal 2025.

View full RedHill Biopharma company overview

RedHill Biopharma annual debt-to-equity ratio history

RedHill Biopharma annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-12-310.25
20232023-12-310.57
20212021-12-319.893.63+57.85%
20202020-12-316.276.20+9758.65%
20192019-12-310.06

RedHill Biopharma debt-to-equity ratio trends

Over the last five fiscal years, RedHill Biopharma's debt-to-equity ratio decreased from 6.27 to 0.25, a change of −6.02. The latest reported quarter, Q4 2025, shows 0.25.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review RedHill Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about RDHL yet. Start the conversation.

Write the first post